gms | German Medical Science

55. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e. V. (DGNC)
1. Joint Meeting mit der Ungarischen Gesellschaft für Neurochirurgie

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

25. bis 28.04.2004, Köln

Monitoring anti-angiogenic treatment by perfusion MRI in an intracerebral glioblastoma model

Perfusions-MRI in einem intrazerebralen Glioblastom-Modell

Meeting Abstract

  • corresponding author Nils Ole Schmidt - Neurosurgical Oncology Laboratory, Brigham & Women's Hospital / Harvard Medical School, Boston /USA; Klinik für Neurochirurgie, Universitätsklinikum HH-Eppendorf, Hamburg
  • Y. Sun - Department of Radiology, Brigham & Women's Hospital / Harvard Medical School, Boston /USA
  • M. Ziu - Neurosurgical Oncology Laboratory, Brigham & Women's Hospital / Harvard Medical School, Boston /USA
  • R. S. Carroll - Neurosurgical Oncology Laboratory, Brigham & Women's Hospital / Harvard Medical School, Boston /USA
  • P. M. Black - Neurosurgical Oncology Laboratory, Brigham & Women's Hospital / Harvard Medical School, Boston /USA

Deutsche Gesellschaft für Neurochirurgie. Ungarische Gesellschaft für Neurochirurgie. 55. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e.V. (DGNC), 1. Joint Meeting mit der Ungarischen Gesellschaft für Neurochirurgie. Köln, 25.-28.04.2004. Düsseldorf, Köln: German Medical Science; 2004. DocP 05.49

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/dgnc2004/04dgnc0332.shtml

Veröffentlicht: 23. April 2004

© 2004 Schmidt et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Objective

Targeting of active angiogenesis which is a major hallmark in many brain tumors, is an attractive adjuvant therapeutic approach. Delivery and scheduling of angiogenesis inhibitors in combination with other therapeutic approaches are of particular importance for the successful clinical integration of anti-angiogenic therapies. In this respect, non invasive MRI-assessed data reflecting pathophysiological changes like tumor blood flow during treatment in a highly reproducible tumor model would help in the development and preclinical evaluation of new anti-angiogenic drugs.

Methods

MRI experiments were performed on a Bruker 8.5 T DRX vertical bore micro-imaging system (Bruker Instruments, Billerica, MA). Continuous arterial spin labeling (CASL) was used to obtain an index of cerebral blood flow (ICBF) in the normal mouse brain and in treated and untreated orthotopic U87 human glioblastoma xenografts. As an anti-angiogenic treatment paradigm, nude mice bearing well-established U87 glioma received daily intraperitoneal injections of a monoclonal antibody against the VEGF-receptor 2 (DC101). Furthermore T2, T1 and Gd-enhanced T1-weighted MR images were obtained.

Results

The mean index of cerebral blood flow (ICBF) in the intracerebral gliomas (n=14) was found to be 50 ± 9 ml/100g/min for tumor core and 209 ± 11 ml/100g/min for normal tissue. The ICBF varied heterogeneously throughout the tumor mass with the tendency to decrease from the periphery to the core of the glioma as demonstrated by color coded perfusion maps and a newly developed radial profile analysis. Our initial results indicated that tumors of animals receiving anti-angiogenic treatment displayed a higher blood flow throughout the tumor mass than those of untreated animals.

Conclusions

Our data support the notion that perfusion MRI can be successfully implemented for assessing the tumor blood flow in an experimental intracerebral glioblastoma model. Treatment effects can be non-invasively monitored over time providing important information for the development of new therapeutic regimens.